Dolutegravir/Lamivudine/Tenofovir Alafenamide

多替拉韦/拉米夫定/艾酚福韦

Report date: 2022/12/07 18:09:08

Base Information

Drug NameDolutegravir/Lamivudine/Tenofovir Alafenamide
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHIV integrase inhibitorsReverse transcriptase inhibitors
TargetsHIV integraseReverse transcriptase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/09/11
Country/TerritoryUnited States
CombinationsYes Dolutegravir SodiumLamivudine
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCipla Usa Inc
China Registration ClassN/A

Develop Information

Active CompaniesMylan Laboratories Ltd
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A